Related references
Note: Only part of the references are listed.Development and validation of Gaucher disease type 1 (GD1)-specific patient-reported outcome measures (PROMs) for clinical monitoring and for clinical trials
Deborahy Elstein et al.
ORPHANET JOURNAL OF RARE DISEASES (2022)
A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility
Ari Gnanasakthy et al.
VALUE IN HEALTH (2022)
The usage of enzyme replacement treatments, economic burden, and quality of life of patients with four lysosomal storage diseases in Shanghai, China
Jiahao Hu et al.
INTRACTABLE & RARE DISEASES RESEARCH (2021)
Agreement between proxy- and self-report scores on PROMIS health-related quality of life domains in pediatric burn survivors: a National Institute on Disability, Independent Living, and Rehabilitation Research Burn Model System Study
Alyssa M. Bamer et al.
QUALITY OF LIFE RESEARCH (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Economic burden and health related quality of life of ultra-rare Gaucher disease in China
Xinye Qi et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Longevity of total hip arthroplasty implants in patients with Gaucher disease
Daniel Cohen et al.
HIP INTERNATIONAL (2020)
Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease, type 1
Andrea G. Alioto et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2020)
Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients
Azza Abdel Gawad Tantawy et al.
NEUROGENETICS (2020)
Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease
Tama Dinur et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Measuring parent proxy-reported quality of life of 11 rare diseases in children in Zhejiang, China
Qisheng Gao et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2020)
Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
Elena Lukina et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Evaluation of the frequency of non-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1
Matheus V. M. B. Wilke et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
Muscle-tendon weakness contributes to chronic fatigue syndrome in Gaucher's disease
Mercedes Roca-Espiau et al.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2019)
The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview
Marielle G. Contesse et al.
ADVANCES IN THERAPY (2019)
Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1
Magdalena Ceron-Rodriguez et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2018)
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols The SPIRIT-PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Improving the usefulness of a tool for appraising the quality of qualitative, quantitative and mixed methods studies, the Mixed Methods Appraisal Tool (MMAT)
Quan Nha Hong et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2018)
Lysosomal storage diseases
Frances M. Platt et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
Health-related quality of life in children and adolescents living with Gaucher disease and their parents
Eduardo Remor et al.
HEALTH PSYCHOLOGY AND BEHAVIORAL MEDICINE (2018)
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Jerome Stirnemann et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Chronic pain in Gaucher disease: skeletal or neuropathic origin?
Grazia Devigili et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Trials
Sarah Acaster
VALUE IN HEALTH (2017)
Patient-Reported Outcome and Observer-Reported Outcome Assessment in Rare Disease Clinical Trials: An ISPOR COA Emerging Good Practices Task Force Report
Katy Benjamin et al.
VALUE IN HEALTH (2017)
Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status
Pilar Giraldo et al.
BLOOD CELLS MOLECULES AND DISEASES (2016)
Meta-analysis of quality of life in children and adolescents with ADHD: By both parent proxy-report and child self-report using PedsQL™
Yi-chen Lee et al.
RESEARCH IN DEVELOPMENTAL DISABILITIES (2016)
Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group
Trevor Richter et al.
VALUE IN HEALTH (2015)
Iron homeostasis and inflammatory biomarker analysis in patients with type 1 Gaucher disease
B. Medrano-Engay et al.
BLOOD CELLS MOLECULES AND DISEASES (2014)
Corrigendum
BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT (2013)
Health-related quality of life and symptom reporting: similarities and differences between children and their parents
Christine Eiser et al.
EUROPEAN JOURNAL OF PEDIATRICS (2013)
Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Acupuncture for symptoms of Gaucher disease
Noah Samuels et al.
COMPLEMENTARY THERAPIES IN MEDICINE (2012)
Testing the reliability and efficiency of the pilot Mixed Methods Appraisal Tool (MMAT) for systematic mixed studies review
Romina Pace et al.
INTERNATIONAL JOURNAL OF NURSING STUDIES (2012)
Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy
Patrick B. Deegan et al.
MEDICINE (2011)
Living With Gaucher Disease: Emotional Health, Psychosocial Needs and Concerns of Individuals With Gaucher Disease
Wendy Packman et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2010)
Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement
Deborah Elstein et al.
BLOOD (2007)
Gaucher disease
Terry D. Butters
CURRENT OPINION IN CHEMICAL BIOLOGY (2007)
Imiglucerase (Cerezyme((R))) improves quality of life in patients with skeletal manifestations of Gaucher disease
N. Weinreb et al.
CLINICAL GENETICS (2007)
Psychological complications of patients with Gaucher disease
W Packman et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2006)
Quality of life related to type 1 Gaucher disease:: Spanish experience
P Giraldo et al.
QUALITY OF LIFE RESEARCH (2005)
A neurological symptom survey of patients with type I Gaucher disease
GM Pastores et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2003)
Share Paper
